Claire Harrison

Professor Claire Harrison graduated from Oxford University Medical School and became a consultant at the Guy’s and St Thomas Hospital in 2001, where she is now a deputy medical director. The focus of her clinical work is myeloproliferative neoplasms (MPN), for which she has a national and international reputation. Key areas of interest are clinical trials and associated translational research.

In addition to the PT-1 trial, MAJIC, COMFORT-II, JAKARTA-2 and PERSIST-1 where she is currently the global chief or co-chief investigator, she has a leadership role in over 20 clinical trials. This work has led to the approval of new therapies such a ruxolitinib, fedratinib and pacritinib. Translational research has been supported with a grant income of over £10M in the past 5 years. JAK2 exon 12 mutations, genetic susceptibility and the impact of the order of mutations in MPN. In the past 10 years she has published widely (>250 academic articles).






If you have any queries about the Meeting arrangements please don’t hesitate to contact us on:
Email: blood@theconferencecompany.com
Telephone (NZ): +64 9 360 1240
Freephone (Aus): 1800 193 405

Postal Address: PO Box 90 040 Auckland, 1142 New Zealand
Street Address: Level 35, International Tower One 100 Barangaroo Avenue, Sydney, NSW, 2000, Australia

The Conference Company

Copyright © 2022 Blood 2023 / Meeting is managed by The Conference Company Designed & Developed by The Conference Company